Advertisement

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Published:December 23, 2015DOI:https://doi.org/10.1016/j.ygyno.2015.12.020

      Highlights

      • Women with BRCA1/2m ovarian cancer and >3 chemotherapy regimens had clinical benefit from olaparib
      • Response rate was higher for patients with platinum-sensitive versus platinum-resistant tumors
      • Duration of response was similar for platinum-sensitive versus platinum-resistant tumors
      • No new safety findings were identified in this heavily pretreated population

      Abstract

      Objective

      The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously.

      Methods

      Eligible patients were treated with oral olaparib 400 mg bid capsule monotherapy until disease progression according to RECIST v1.1. Objective response rate (ORR) and duration of response (DoR) were assessed for patients with measurable disease at baseline. Safety and tolerability were assessed for all patients by adverse event (AE) incidence and changes in laboratory parameters. Platinum resistance status was obtained retrospectively, and responses to olaparib evaluated.

      Results

      In patients with gBRCA1/2m ovarian cancer, 154/193 (80%) had received ≥3 prior lines of chemotherapy, of whom 137/154 (89%) had measurable disease at baseline. ORR was 34% (46/137; 95% confidence interval [CI] 26–42) and median DoR was 7.9 (95% CI 5.6–9.6) months. ORR in platinum-resistant tumors was 30%. Median DoR for platinum-sensitive and platinum-resistant disease was similar: 8.2 months (95% CI 5.6–13.5) compared with 8.0 months (4.8–14.8), respectively. Six of the 193 (3%) patients had an AE with an outcome of death. None of these AEs at time of occurrence was considered causally related to olaparib.

      Conclusion

      Following ≥3 prior lines of chemotherapy, olaparib 400 mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer. No new safety signals were identified.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.
        • Ma J.
        • Zou Z.
        • Jemal A.
        Cancer statistics, 2014.
        CA Cancer J. Clin. 2014; 64: 9-29
        • Pfisterer J.
        • Plante M.
        • Vergote I.
        • du Bois A.
        • Hirte H.
        • Lacave A.J.
        • et al.
        Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
        J. Clin. Oncol. 2006; 24: 4699-4707
        • Pujade-Lauraine E.
        • Wagner U.
        • Aavall-Lundqvist E.
        • Gebski V.
        • Heywood M.
        • Vasey P.A.
        • et al.
        Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
        J. Clin. Oncol. 2010; 28: 3323-3329
        • Parmar M.K.
        • Ledermann J.A.
        • Colombo N.
        • du Bois A.
        • Delaloye J.F.
        • Kristensen G.B.
        • et al.
        Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
        Lancet. 2003; 361: 2099-2106
        • Alberts D.S.
        • Liu P.Y.
        • Wilczynski S.P.
        • Clouser M.C.
        • Lopez A.M.
        • Michelin D.P.
        • et al.
        Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
        Gynecol. Oncol. 2008; 108: 90-94
        • Hanker L.C.
        • Loibl S.
        • Burchardi N.
        • Pfisterer J.
        • Meier W.
        • Pujade-Lauraine E.
        • et al.
        The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.
        Ann. Oncol. 2012; 23: 2605-2612
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • et al.
        Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 852-861
        • Kaufman B.
        • Shapira-Frommer R.
        • Schmutzler R.K.
        • Audeh M.W.
        • Friedlander M.
        • Balmaña J.
        • et al.
        Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation.
        J. Clin. Oncol. 2015; 33: 244-250
        • Kim G.
        • Ison G.
        • McKee A.E.
        • Zhang H.
        • Tang S.
        • Gwise T.
        • et al.
        FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy.
        Clin. Cancer Res. 2015; 21: 4257-4261
        • AstraZeneca
        Global Policy: Bioethics.
        2015 (Available at: http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies)
        • Fong P.C.
        • Boss D.S.
        • Yap T.A.
        • Tutt A.
        • Wu P.
        • Mergui-Roelvink M.
        • et al.
        Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
        N. Engl. J. Med. 2009; 361: 123-134
        • Fong P.C.
        • Yap T.A.
        • Boss D.S.
        • Carden C.P.
        • Mergui-Roelvink M.
        • Gourley C.
        • et al.
        Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
        J. Clin. Oncol. 2010; 28: 2512-2519
        • Audeh M.W.
        • Carmichael J.
        • Penson R.T.
        • Friedlander M.
        • Powell B.
        • Bell-McGuinn K.M.
        • et al.
        Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 245-251
        • Gelmon K.A.
        • Tischkowitz M.
        • Mackay H.
        • Swenerton K.
        • Robidoux A.
        • Tonkin K.
        • et al.
        Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
        Lancet Oncol. 2011; 12: 852-861
        • Kaye S.B.
        • Lubinski J.
        • Matulonis U.
        • Ang J.E.
        • Gourley C.
        • Karlan B.Y.
        • et al.
        Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
        J. Clin. Oncol. 2012; 30: 372-379
        • Sandhu S.K.
        • Yap T.A.
        • de Bono J.S.
        The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment.
        Curr. Drug Targets. 2011; 12: 2034-2044